Table: Brightpath Biotherapeutics - Q1 parent results

BrightPath Biotherapeutics Co

12/08/2022 07:00

Aug 12 (Reuters)- 
             Brightpath Biotherapeutics Co., Ltd. 
             PARENT-ONLY FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)                
                 3 months ended      3 months ended        Year to  
                Jun 30, 2022        Jun 30, 2021      Mar 31, 2023  
                   LATEST             YEAR-AGO           LATEST     
                   RESULTS             RESULTS          FORECAST    
  Sales             0 mln               0 mln             5 mln     
                 (-50.0 pct)         (-33.3 pct)       (-67.6 pct)  
  Operating     loss 545 mln        loss 402 mln        loss 1.64   
  Recurring     loss 548 mln        loss 403 mln        loss 1.64   
  Net           loss 548 mln        loss 402 mln        loss 1.64   
  EPS           loss 9.75 yen       loss 7.93 yen    loss 29.63 yen 
  Ann Div                                NIL               NIL      
  -Q2 div                                NIL               NIL      
  -Q4 div                                NIL               NIL      
  
  NOTE - Brightpath Biotherapeutics Co., Ltd.. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4594.T